Corcept Therapeutics (CORT) Stock: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$116.28
-0.17 (-0.15%)
▼
5d:
+0.04%
30d:
-1.04%
90d:
+20.3%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 03, 2026
11d
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CORT shows positive signals but monitor for confirmation. Market pricing in 10.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CORT shows positive signals but monitor for confirmation. Market pricing in 10.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$214.45
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$133.16
12.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $116.28, which is considered fair relative to its 30-day fair value range of $112.37 to $118.97. From a valuation perspective, the stock is trading at a discount (Forward PE: 26.4) compared to its historical average (36.6). Remarkably, the market is currently pricing in an annual earnings decline of 10.3% over the next few years. This pessimistic expectation contrasts with the company's recent 24.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $107.79, while resistance sits at $122.81.
Market Sentiment: CORT scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $141.00 (+21.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $107.79, while resistance sits at $122.81.
Market Sentiment: CORT scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $141.00 (+21.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$112.37 -
$118.97
Company Quality Score
55/100
(HOLD)
Options IV Signal
38th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 38th percentile)
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.3% below Wall St target ($141.00)
- BULLISH: Bottoming setup score 61/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$112.37 -
$118.97
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$10.31
(8.9%)
Support & Resistance Levels
Support Level
$107.79
Resistance Level
$122.81
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.40
Wall Street Target
$141.00
(+21.3%)
Revenue Growth (YoY)
31.7%
Earnings Growth (YoY)
24.1%
Profit Margin
6.6%
Valuation Discount vs History
-10.3% cheaper
PE vs Historical
26.4 vs 36.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.3%
(market-implied from PE analysis)
1-Year Target
$104.65
(-10%)
2-Year Target
$94.19
(-19%)
3-Year Target
$84.77
(-27%)
3-Yr Target (if PE normalizes)
(PE: 26→37)
$117.53
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.4, Growth: 107.8%)
$392.44
(+238%)
Base:
(SPY PE: 19.9, Growth: 107.8%)
$295.26
(+154%)
Bear:
(PE: 16.9, Growth: 107.8%)
$250.97
(+116%)
📈
Valuation based on Current Earnings
Forward PE: 19.30 | Forward EPS (Implied): $6.02
Bull Case
$140.41
(+21%)
Analyst growth 15.0%, PE expands to 20.3
Base Case
$116.28
(0%)
Market implied 0.0%, PE stable at 19.3
Bear Case
$88.95
(-24%)
Severe decline -15.0%, PE contracts to 17.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 26.4 to 36.6
Stabilization Target:
$161.22
(+38.7%)
PE Expansion Potential:
+38.7%
Share & Embed Analysis
Last updated: October 21, 2026 8:07 PM ET
Data refreshes hourly during market hours. Next update: 9:07 PM
Data refreshes hourly during market hours. Next update: 9:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 47 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 71 BUY |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 74 BUY |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
